TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06807021: Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double- Blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Mitigation of Cutaneous Scarring in Skin Graft and Donor Sites

Sponsor: Birch BioMed Inc · Phase: PHASE2/PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,382,396

Rescue Site Savings

+$3,556,788

Unlock Full NCT06807021 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06807021 Rescue Dossier →